CL2021000724A1 - Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 - Google Patents
Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3Info
- Publication number
- CL2021000724A1 CL2021000724A1 CL2021000724A CL2021000724A CL2021000724A1 CL 2021000724 A1 CL2021000724 A1 CL 2021000724A1 CL 2021000724 A CL2021000724 A CL 2021000724A CL 2021000724 A CL2021000724 A CL 2021000724A CL 2021000724 A1 CL2021000724 A1 CL 2021000724A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- disease
- aging
- compositions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737017P | 2018-09-26 | 2018-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000724A1 true CL2021000724A1 (es) | 2021-10-15 |
Family
ID=69953286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000724A CL2021000724A1 (es) | 2018-09-26 | 2021-03-23 | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3856195A4 (fr) |
JP (1) | JP2022502441A (fr) |
KR (1) | KR20210065950A (fr) |
CN (1) | CN112789044A (fr) |
AU (1) | AU2019346456A1 (fr) |
BR (1) | BR112021004938A2 (fr) |
CA (1) | CA3111433A1 (fr) |
CL (1) | CL2021000724A1 (fr) |
CO (1) | CO2021003713A2 (fr) |
EA (1) | EA202190463A1 (fr) |
IL (1) | IL281578A (fr) |
MA (1) | MA53743A (fr) |
MX (1) | MX2021002967A (fr) |
SG (1) | SG11202102105VA (fr) |
TW (1) | TW202027752A (fr) |
WO (1) | WO2020069008A1 (fr) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
EP1996551A2 (fr) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Derives de piperidine, leur procede de preparation, leur utilisation comme agents therapeutiques et compositions pharmaceutiques les contenant |
US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
DK2749554T3 (en) * | 2009-04-22 | 2018-04-03 | Sma Therapeutics Inc | 2,5-disubstituted arylsulfonamide CCR3 antagonists |
US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
KR102658724B1 (ko) * | 2017-04-05 | 2024-04-18 | 알카헤스트 인코포레이티드 | Ccr3-저해제를 사용하여 망막-관련 질병을 치료하는 방법 및 조성물 |
CA3058967A1 (fr) * | 2017-04-05 | 2018-10-11 | Alkahest, Inc. | Methodes et compositions destinees a traiter des troubles associes au vieillissement a l'aide d'inhibiteurs de ccr3 |
-
2019
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/fr active Pending
- 2019-09-25 CA CA3111433A patent/CA3111433A1/fr active Pending
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/fr active Application Filing
- 2019-09-25 JP JP2021517342A patent/JP2022502441A/ja active Pending
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko unknown
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3856195A4 (fr) | 2022-06-22 |
MA53743A (fr) | 2022-01-05 |
CO2021003713A2 (es) | 2021-04-08 |
IL281578A (en) | 2021-05-31 |
AU2019346456A1 (en) | 2021-04-15 |
TW202027752A (zh) | 2020-08-01 |
CA3111433A1 (fr) | 2020-04-02 |
EP3856195A1 (fr) | 2021-08-04 |
JP2022502441A (ja) | 2022-01-11 |
WO2020069008A1 (fr) | 2020-04-02 |
MX2021002967A (es) | 2021-08-11 |
CN112789044A (zh) | 2021-05-11 |
BR112021004938A2 (pt) | 2021-06-01 |
SG11202102105VA (en) | 2021-04-29 |
EA202190463A1 (ru) | 2021-06-29 |
KR20210065950A (ko) | 2021-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019012164A2 (es) | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 | |
CL2018002777A1 (es) | Compuesto heterocíclico | |
CL2019000787A1 (es) | Métodos para tratar trastornos mitocondriales y metabólicos. | |
BR112017009647A2 (pt) | 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer | |
TN2018000322A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
NI201700055A (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
CO2021015264A2 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
ECSP20042640A (es) | Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer | |
PH12019501371A1 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORy AND OTHERS USES | |
BR112018006445A2 (pt) | métodos para tratar distrofia muscular | |
BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
EA201991756A1 (ru) | Бисгетероарильные производные в качестве модуляторов агрегации белков | |
BR112022021962A2 (pt) | Imidazopiridazinas como moduladores de il-17 | |
WO2020058979A3 (fr) | Méthodes de traitement de la sclérose latérale amyotrophique | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
BR112019003594A2 (pt) | sistemas depot que compreendem acetato de glatirâmero | |
BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
WO2021100029A3 (fr) | Promédicaments de fulvestrant | |
CO2021003713A2 (es) | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 | |
WO2020117031A3 (fr) | Composition et méthode d'inhibition de l'accumulation et/ou de l'agrégation de bêta-amyloïdes | |
PE20220384A1 (es) | Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares | |
EA201992188A1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
WO2016122943A3 (fr) | Composés, compositions et procédés d'utilisation d'hla-f | |
JP1724081S (ja) | 保護眼鏡 |